This project, titled "Application of an AI-Based Health Management System in Long-Term Epilepsy Management in Rural Areas ", is led by the First Affiliated Hospital of Air Force Medical University, with Jiang Wen as the principal investigator. It is a prospective, multicenter, cluster-randomized controlled trial involving 756 patients from eight rural counties in China's northwest region. The study aims to evaluate the effectiveness of an AI-assisted remote healthcare system (via a WeChat mini-program) compared to standard care in reducing seizure frequency and improving self-management skills among adult epilepsy patients. Key components include patient and doctor interfaces for features like AI consultations, medication reminders, and online consultations. The trial runs from December 1, 2025, to November 30, 2027, with primary outcomes measured at 12 months and secondary outcomes assessing medication adherence, quality of life, and safety.

Inclusion Criteria:

• Meets ILAE 2017 diagnostic criteria for epilepsy.
• ≥1 bilateral tonic-clonic seizure in the past 12 months.
• Aged 18-65 years.
• Access to a smartphone patient/caregiver.
• Written informed consent.

Exclusion Criteria:

• Pregnancy, lactation, or planned pregnancy.
• Seizures with identifiable triggers e.g., alcohol withdrawal.
• Allergy to phenobarbital/sodium valproate.
• Severe comorbidities e.g., organ dysfunction, malignancy, psychiatric disorders.

IPD will not be shared due to privacy constraints, contractual agreements.